UniQure triples after brain disorder therapy slows disease progression in trial

U.S.-listed shares of uniQure UQ1.F, QURE.O more than triple to a near five-year high of $47.37

*Stock set for its best day ever, if gains hold

The Netherlands-based drugmaker says its experimental gene therapy significantly slowed progression of a brain disorder in early-to-mid stage study

QURE is developing a therapy called AMT-130 to treat Huntington's disease, a rare inherited brain disorder that progressively impairs movement, thinking, and behavior, ultimately leading to severe disability and death

Separately, QURE says it secured a $175 million loan from Hercules Capital HTGC.N to support the potential U.S. launch of AMT-130

Including session's move, stock up 162.1% YTD